Adamis Pharmaceuticals Corp (NASDAQ:ADMP) gets downgraded to Hold by Maxim Group

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) is Buy with a consensus target price of $3.70 per share, a potential 487.30% upside.

Some recent analyst ratings include

• 11/25/2019-
  Adamis Pharmaceuticals Corp (NASDAQ:ADMP) gets downgraded to Hold by Maxim Group
• 7/23/2019-
  Adamis Pharmaceuticals Corp (NASDAQ:ADMP) gets upgraded to Neutral by B. Riley
• 7/2/2019-
  Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has coverage initiated with a Buy rating

  • On 11/18/2019 David J Marguglio, SVP, sold 8,283 with an average share price of $0.87 per share and the total transaction amounting to $7,206.21.
  • On 11/18/2019 Dennis J Phd Carlo, CEO, sold 10,760 with an average share price of $0.84 per share and the total transaction amounting to $9,038.40.
  • On 11/18/2019 Karen K Daniels, VP, sold 5,421 with an average share price of $0.83 per share and the total transaction amounting to $4,499.43.
  • On 11/18/2019 Robert O Hopkins, CFO, sold 7,347 with an average share price of $0.83 per share and the total transaction amounting to $6,098.01.
  • On 11/18/2019 Ronald B Moss, Insider, sold 8,448 with an average share price of $0.85 per share and the total transaction amounting to $7,180.80.
  • On 8/19/2019 David J Marguglio, SVP, sold 8,109 with an average share price of $1.10 per share and the total transaction amounting to $8,919.90.
  • On 8/19/2019 Dennis J Phd Carlo, CEO, sold 10,477 with an average share price of $1.06 per share and the total transaction amounting to $11,105.62.

  Recent Trading Activity for

  Adamis Pharmaceuticals Corp (NASDAQ:ADMP)
  Shares of

  Adamis Pharmaceuticals Corp closed the previous trading session at with shares trading hands.

  Exit mobile version